San Diego-dependent Viking Therapeutics marked itself as a significant competitor while in the weight loss drug market in February immediately after revealing promising information from a mid-stage trial of experimental drug VK2735, which instructed it rivaled—and outperformed—Novo and Lilly drugs when presented like a weekly injection and in M